Virbac remains an attractive animal healthcare play
03/05/24 -"We have rolled forward our model to include a new forecast year (2026) which will also see continued healthy top-line growth and profitability improvements (that we foresee to start from 2025 ..."
Pages
55
Language
English
Published on
03/05/24
You may also be interested by these reports :
17/05/24
We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of ...
15/05/24
The Q1 results surpassed the consensus estimates, driven by a sustained strong performance from the strategic products. The management nonetheless ...
15/05/24
Merck started the year well, with Electronics being the largest contributor, demonstrating organic sales growth after several stagnant quarters. ...
15/05/24
The Q1 results largely met the consensus, as the firm’s key blood-plasma-derived proteins witnessed strong demand, profitability continued to expand ...